The Diversity of Liquid Biopsies and Their Potential in Breast Cancer Management
Analyzing blood as a so-called liquid biopsy in breast cancer (BC) patients has the potential to adapt therapy management. Circulating tumor cells (CTCs), extracellular vesicles (EVs), cell-free DNA (cfDNA) and other blood components mirror the tumoral heterogeneity and could support a range of clin...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-11-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/15/22/5463 |
| _version_ | 1797459829926658048 |
|---|---|
| author | Corinna Keup Rainer Kimmig Sabine Kasimir-Bauer |
| author_facet | Corinna Keup Rainer Kimmig Sabine Kasimir-Bauer |
| author_sort | Corinna Keup |
| collection | DOAJ |
| description | Analyzing blood as a so-called liquid biopsy in breast cancer (BC) patients has the potential to adapt therapy management. Circulating tumor cells (CTCs), extracellular vesicles (EVs), cell-free DNA (cfDNA) and other blood components mirror the tumoral heterogeneity and could support a range of clinical decisions. Multi-cancer early detection tests utilizing blood are advancing but are not part of any clinical routine yet. Liquid biopsy analysis in the course of neoadjuvant therapy has potential for therapy (de)escalation.Minimal residual disease detection via serial cfDNA analysis is currently on its way. The prognostic value of blood analytes in early and metastatic BC is undisputable, but the value of these prognostic biomarkers for clinical management is controversial. An interventional trial confirmed a significant outcome benefit when therapy was changed in case of newly emerging cfDNA mutations under treatment and thus showed the clinical utility of cfDNA analysis for therapy monitoring. The analysis of PIK3CA or ESR1 variants in plasma of metastatic BC patients to prescribe targeted therapy with alpesilib or elacestrant has already arrived in clinical practice with FDA-approved tests available and is recommended by ASCO. The translation of more liquid biopsy applications into clinical practice is still pending due to a lack of knowledge of the analytes’ biology, lack of standards and difficulties in proving clinical utility. |
| first_indexed | 2024-03-09T16:56:32Z |
| format | Article |
| id | doaj.art-44bb16728ba64f1f90f642b7904a9ee8 |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-09T16:56:32Z |
| publishDate | 2023-11-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-44bb16728ba64f1f90f642b7904a9ee82023-11-24T14:34:37ZengMDPI AGCancers2072-66942023-11-011522546310.3390/cancers15225463The Diversity of Liquid Biopsies and Their Potential in Breast Cancer ManagementCorinna Keup0Rainer Kimmig1Sabine Kasimir-Bauer2Department of Gynecology and Obstetrics, University Hospital of Essen, 45147 Essen, GermanyDepartment of Gynecology and Obstetrics, University Hospital of Essen, 45147 Essen, GermanyDepartment of Gynecology and Obstetrics, University Hospital of Essen, 45147 Essen, GermanyAnalyzing blood as a so-called liquid biopsy in breast cancer (BC) patients has the potential to adapt therapy management. Circulating tumor cells (CTCs), extracellular vesicles (EVs), cell-free DNA (cfDNA) and other blood components mirror the tumoral heterogeneity and could support a range of clinical decisions. Multi-cancer early detection tests utilizing blood are advancing but are not part of any clinical routine yet. Liquid biopsy analysis in the course of neoadjuvant therapy has potential for therapy (de)escalation.Minimal residual disease detection via serial cfDNA analysis is currently on its way. The prognostic value of blood analytes in early and metastatic BC is undisputable, but the value of these prognostic biomarkers for clinical management is controversial. An interventional trial confirmed a significant outcome benefit when therapy was changed in case of newly emerging cfDNA mutations under treatment and thus showed the clinical utility of cfDNA analysis for therapy monitoring. The analysis of PIK3CA or ESR1 variants in plasma of metastatic BC patients to prescribe targeted therapy with alpesilib or elacestrant has already arrived in clinical practice with FDA-approved tests available and is recommended by ASCO. The translation of more liquid biopsy applications into clinical practice is still pending due to a lack of knowledge of the analytes’ biology, lack of standards and difficulties in proving clinical utility.https://www.mdpi.com/2072-6694/15/22/5463liquid biopsybloodbreast neoplasmprecision medicineearly detection of cancerresidual neoplasm |
| spellingShingle | Corinna Keup Rainer Kimmig Sabine Kasimir-Bauer The Diversity of Liquid Biopsies and Their Potential in Breast Cancer Management Cancers liquid biopsy blood breast neoplasm precision medicine early detection of cancer residual neoplasm |
| title | The Diversity of Liquid Biopsies and Their Potential in Breast Cancer Management |
| title_full | The Diversity of Liquid Biopsies and Their Potential in Breast Cancer Management |
| title_fullStr | The Diversity of Liquid Biopsies and Their Potential in Breast Cancer Management |
| title_full_unstemmed | The Diversity of Liquid Biopsies and Their Potential in Breast Cancer Management |
| title_short | The Diversity of Liquid Biopsies and Their Potential in Breast Cancer Management |
| title_sort | diversity of liquid biopsies and their potential in breast cancer management |
| topic | liquid biopsy blood breast neoplasm precision medicine early detection of cancer residual neoplasm |
| url | https://www.mdpi.com/2072-6694/15/22/5463 |
| work_keys_str_mv | AT corinnakeup thediversityofliquidbiopsiesandtheirpotentialinbreastcancermanagement AT rainerkimmig thediversityofliquidbiopsiesandtheirpotentialinbreastcancermanagement AT sabinekasimirbauer thediversityofliquidbiopsiesandtheirpotentialinbreastcancermanagement AT corinnakeup diversityofliquidbiopsiesandtheirpotentialinbreastcancermanagement AT rainerkimmig diversityofliquidbiopsiesandtheirpotentialinbreastcancermanagement AT sabinekasimirbauer diversityofliquidbiopsiesandtheirpotentialinbreastcancermanagement |